Objective: To investigate the diphtheria antibody level in healthy population in Beijing.

Methods: 10 age groups (< 1, 1 to 4, 5 to 9, 10 to 14, 15 to 19, 20 to 24, 25 to 29, 30 to 34, 35 to 39, and > or =40) were sampled by the Multi-stage stratified sampling method in 9 districts in Beijing, and 2 003 sera from healthy population were collected. The diphtheria antibody was determined with ELISA method.

Results: The diphtheria antibody-positive rate was 60.26%, and the antibody concentration was 0.62 IU/ml. A trend of decreasing in the antibody concentration was observed with increasing age and years after immunization. Antibody levels were the lowest in healthy people between 25-40 years old.

Conclusion: It was predicted that a large scale of diphtheria outbreak would not occur recently in Beijing. It is recommended that for all adults diphtheria toxoids booster immunization should be conducted every 10 years for all adults.

Download full-text PDF

Source

Publication Analysis

Top Keywords

diphtheria antibody
12
healthy population
12
antibody levels
8
antibody concentration
8
antibody
6
diphtheria
5
[analysis diphtheria
4
healthy
4
levels healthy
4
population beijing
4

Similar Publications

Inhibition of aortic CX3CR1+ macrophages mitigates thoracic aortic aneurysm progression in Marfan syndrome in mice.

J Clin Invest

January 2025

Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University; State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing, China.

The pathogenesis of thoracic aortic aneurysm (TAA) in Marfan syndrome (MFS) is generally attributed to vascular smooth muscle cell (VSMC) pathologies. However, the role of immune cell-mediated inflammation remains elusive. Single-cell RNA sequencing identified a subset of CX3CR1+ macrophages mainly located in the intima in the aortic roots and ascending aortas of Fbn1C1041G/+ mice, further validated in MFS patients.

View Article and Find Full Text PDF

: The development of a five-in-one vaccine microneedle patch (five-in-one MN patch) aims to address challenges in administering vaccines against Diphtheria (DT), Tetanus (TT), Pertussis (wP), Hepatitis B (HBsAg), and type b (Hib). Combining multiple vaccines into a single patch offers a novel solution to improve vaccine accessibility, stability, and delivery efficiency, particularly in resource-limited settings. : The five-in-one MN patch consists of four distinct microneedle arrays: DT and TT vaccines are coated together on one array, while wP, HepB, and Hib vaccines are coated separately on individual arrays.

View Article and Find Full Text PDF

A post hoc analysis of maternally derived antibodies at birth and age 2 months following second trimester maternal Tdap vaccination between 20 and 24 weeks' gestational age (GA) showed a faster decay rate of Tdap-related immunoglobulin G in early preterms born before 32 weeks' GA compared with moderate-to-late preterms and full-terms. This is different from previous studies and merits further research.

View Article and Find Full Text PDF

TIGIT CD4 regulatory T cells enhance PD-1 expression on CD8 T cells and promote tumor growth in a murine ovarian cancer model.

J Ovarian Res

December 2024

Department of Gynecology and Obstetrics, The Affiliated Hospital of Nankai University, Tianjin No. 4 Hospital, Tianjin, 300222, China.

Immune checkpoint-based immunotherapy has shown limited efficacy in the treatment of ovarian cancer. In recent years, the emergence of immune checkpoint co-targeting therapies, led by the combination targeting of TIGIT and FAK, has shown promise in ovarian cancer treatment. Our preliminary research indicates that TIGIT is predominantly expressed in regulatory T cells during ovarian cancer.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the safety and immunogenicity of a TdaP vaccine for pregnant women living with HIV, aiming to protect infants from severe pertussis disease.
  • Conducted in Uganda, the trial randomly assigned 181 women (HIV-positive and HIV-negative) to receive either the TdaP or Td vaccine, evaluating immune responses in infants post-delivery.
  • Findings will provide valuable insights into the vaccine's effectiveness and safety for this specific population, contributing to better health outcomes for mothers and their babies.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!